Syringe News and Research

RSS

BioLife becomes the leading supplier of pre-formulated cord blood stem cell freeze media products

BioLife Solutions, Inc., a leading developer and manufacturer of clinical grade biopreservation media products for cells and tissues, today announced that it has become the leading supplier of pre-formulated GMP cryopreservation media for umbilical cord blood stem cells, a key segment of the Company's strategic biobanking market.

21 Jun 2011

FDA's draft guidance document addresses artificial pancreas system for type 1 diabetes

The U.S. Food and Drug Administration today issued draft guidance that will help advance the development and approval of an artificial pancreas system to treat type 1 diabetes in the United States.

21 Jun 2011

EC approves Biogen Idec's AVONEX PEN to treat multiple sclerosis

Biogen Idec announced today that the European Commission (EC) has granted approval to AVONEX PEN for patients with relapsing multiple sclerosis (MS) and patients who have had a single demyelinating event.

7 Jun 2011

Repro-Med Systems receives FDA marketing approval for new subcutaneous needle sets

Repro-Med Systems, Inc., announced today that it has received approval from the Food and Drug Administration to begin U.S. marketing of its new Subcutaneous Needle Sets which the company is promoting as the HIgh Flo RMS Subcutaneous Needle Sets.

1 Jun 2011

Cellix Inks OEM supply agreement with Cell Biolabs

Cellix are pleased to announce the signing of an OEM manufacture and supply agreement with Cell Biolabs on a range of microfluidic biochips and accessories for cell-based assays. Cell-Biolabs, based in San Diego, CA, will supply the biochips from their current Cell-Based Assay product range thereby diversifying their product portfolio and entering into the microfluidics field.

23 May 2011

More HIV infections linked to injection drug use in East Africa, report finds

A.P. Pharma targets resubmission of APF530 NDA in 2012

A.P. Pharma, Inc., a specialty pharmaceutical company, today provided an update on its lead product candidate, APF530, for the prevention of chemotherapy-induced nausea and vomiting (CINV).

25 Apr 2011

Prism Pharmaceuticals to be acquired by Baxter

Ligand Pharmaceuticals Incorporated announced that its partner Prism Pharmaceuticals has entered into a definitive agreement to be acquired by Baxter International Inc.. Prism Pharmaceuticals recently received FDA approval for Nexterone®, an antiarrhythmic agent which Ligand (through its CyDex Pharmaceuticals subsidiary) originally developed with its patented Captisol® formulation technology and licensed to Prism in 2006.

From Baxter International Inc. 20 Apr 2011

Medtronic launches MARROWMAX Bone Marrow Aspiration Needle Kit in the U.S.

Expanding its leading bone grafting portfolio, Medtronic, Inc. today announced the U.S. launch of the MARROWMAX™ Bone Marrow Aspiration Needle Kit.

20 Apr 2011

EMA CHMP grants positive opinion for Biogen Idec's AVONEX PEN

Biogen Idec announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of AVONEX® PEN™ for patients with relapsing multiple sclerosis (MS) and patients with a single demyelinating event.

19 Apr 2011

Baxter enters definitive agreement to acquire Prism

Baxter International Inc. announced today that it has entered into a definitive agreement to acquire privately-held Prism Pharmaceuticals, Inc., a specialty pharmaceutical company based in King of Prussia, PA. Prism Pharmaceuticals has developed and received U.S. Food and Drug Administration (FDA) approval for multiple presentations of NEXTERONE® (amiodarone HCl), an antiarrhythmic agent.

From Baxter International Inc. 18 Apr 2011

Cellix expands European distribution network with Tebu-bio

Cellix are pleased to announce the signing of a distribution agreement with tebu-bio SAS. tebu-bio has a well-established pan-European presence, recognised by the international scientific community with local offices in France, Germany, Belgium, the Netherlands, Italy, Denmark, Portugal, Spain and the UK.

11 Apr 2011

Watson, GeneraMedix receive FDA approval for Nulecit to treat iron deficiency anemia

Watson Pharmaceuticals, Inc. today announced that it is initiating launch activities of Nulecit, following FDA approval of GeneraMedix Inc.'s, Abbreviated New Drug Application.

1 Apr 2011

Repro-Med Systems net revenue increases 30% for fiscal year ending February 28, 2011

Repro-Med Systems, Inc., dba RMS Medical Products, today announced unaudited financial results for its fiscal year ended February 28, 2011, showing increases in both domestic and international sales.

31 Mar 2011

Unilife initiates Unifill syringe production for pharmaceutical companies

Unilife Corporation today announced it has commenced initial production of the Unifill ready-to-fill syringe at its FDA-registered manufacturing facility in York, Pennsylvania.

30 Mar 2011

EDT receives European approval for XEPLION injection to treat schizophrenia

Elan Drug Technologies, the drug delivery unit of Elan Corporation, plc, today announced that the first injectable product using EDT's NanoCrystal technology has been approved by the European Commission.

9 Mar 2011

Excelsior medical's SwabFlush receives FDA 510(k) clearance

Excelsior Medical Corporation announced today that it has received FDA 510(k) clearance for SwabFlush™, its latest product for the vascular access and infection control markets.

8 Mar 2011

Mindray Medical enters agreement to acquire controlling stake of Shenke

Mindray Medical International Limited, a leading developer, manufacturer and marketer of medical devices worldwide, announced today an agreement to acquire a controlling stake of Shenzhen Shenke Medical Instrument Technical Development Co. Ltd. The terms of the transaction were not disclosed as the transaction is non-material to Mindray's financial statements.

From Mindray 28 Feb 2011

First patient treated in KUR-023 pilot clinical trial to assess safety and efficacy of product candidate

Kuros Biosurgery AG, a biotechnology company focused on the development of novel biomaterials and bioactive-biomaterial combination products for trauma, wound and spinal indications, announced today that it has treated the first patient in a pilot clinical trial investigating the safety and efficacy of KUR-023, its novel dural sealant product candidate.

28 Feb 2011

Inexpensive drug therapy shows promise in treating premature infants with childhood blindness

A readily available, inexpensive drug therapy showed a significant benefit in treating premature infants with the worst and historically most difficult-to-treat cases of retinopathy of prematurity.

17 Feb 2011